Biogen Inc. and Samsung Bioepis announced that they will present new real-world data from the companies’ anti-TNF biosimilar portfolio, which includes FLIXABI (infliximab) and IMRALDI (adalimumab). These data, which provide further insight into the long-term safety and efficacy as well as patient experience with anti-TNF biosimilars, are being presented at United European Gastroenterology (UEG) Week 2019 taking place in Barcelona, Spain (October 19-23).
Biosimilars are products that are demonstrated to be highly similar to reference biological product and have the potential to lower drug costs. In Europe, approximately 170,000 patients have been treated with Biogen and Samsung Bioepis’ anti-TNF biosimilars. Biogen expects the uptake of these products to generate 1.8 billion euros in healthcare cost savings in 2019.
“Patients living with severe autoimmune diseases such as IBD are looking for long-term treatments to safely and effectively control symptoms and improve their quality of life. Biosimilars now open the door for more patients to access biologic medicines and effectively manage their GI diseases,” said Alessandro Armuzzi, M.D., Ph.D., Head, Inflammatory Bowel Disease Unit Complesso Integrato Columbus Catholic University of Rome/Italy.